Elicio Therapeutics (ELTX) EBITDA Margin (2020 - 2022)
Elicio Therapeutics' (ELTX) quarterly EBITDA Margin came in at 954.36% in Q2 2022, up 242415.0% on a YoY basis from N/an in Q2 2021, and down 8.58% quarter-over-quarter from 878.94% in Q1 2022.
Powered by 
Analysis
Elicio Therapeutics (ELTX) EBITDA Margin (2020 - 2022) Analysis & Trends
Elicio Therapeutics (ELTX) has reported EBITDA Margin for 3 consecutive years, with 954.36% the latest figure, recorded in Q2 2022.
- For the quarter ending Q2 2022, EBITDA Margin rose 242415.0% year-over-year to 954.36%; the trailing twelve-month figure through Mar 2023 stood at 3946.09% (down 383168.0% YoY), and the FY2022 full-year result was 1031.42%, down 89259.0% from the prior year.
- EBITDA Margin declined to 954.36% in Q2 2022 per ELTX's latest filing, from 878.94% in the prior quarter.
- Across five years, EBITDA Margin topped out at 56.41% in Q4 2021 and bottomed at 5374.39% in Q1 2021.
- Historically, EBITDA Margin has averaged 1984.93% across 3 years, with a median of 1426.96% in 2020.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin tumbled 392133 bps in 2021, then surged 449545 bps in 2022.
- Over 3 years, EBITDA Margin stood at 3017.43% in 2020, then surged by 102 bps to 56.41% in 2021, then sank by 1792 bps to 954.36% in 2022.
- According to Business Quant data, EBITDA Margin over the past three periods registered 954.36%, 878.94%, and 56.41% for Q2 2022, Q1 2022, and Q4 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Elicio Therapeutics | 40.60 Mn | 17.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | -954.36% |
| Mar 31, 2022 | -878.94% |
| Dec 31, 2021 | 56.41% |
| Sep 30, 2021 | -1,079.32% |
| Jun 30, 2021 | -3,378.52% |
| Mar 31, 2021 | -5,374.39% |
| Dec 31, 2020 | -3,017.43% |
| Sep 30, 2020 | -1,400.85% |
| Jun 30, 2020 | -2,368.86% |
| Mar 31, 2020 | -1,453.06% |